Literature DB >> 16818714

ABCB1 2677G>T/A genotype and paclitaxel pharmacogenetics in ovarian cancer.

Sharon Marsh, Cristi R King, Howard L McLeod, Jim Paul, Gillian Gifford, Robert Brown.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16818714     DOI: 10.1158/1078-0432.CCR-06-0461

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  5 in total

Review 1.  Germline genetic variants with implications for disease risk and therapeutic outcomes.

Authors:  Amy L Pasternak; Kristen M Ward; Jasmine A Luzum; Vicki L Ellingrod; Daniel L Hertz
Journal:  Physiol Genomics       Date:  2017-09-08       Impact factor: 3.107

2.  No Association between ABCB1 G2677T/A or C3435T Polymorphisms and Survival of Breast Cancer Patients-A 10-Year Follow-Up Study in the Polish Population.

Authors:  Ewa Totoń; Barbara Jacczak; Wojciech Barczak; Paweł Jagielski; Robert Gryczka; Hanna Hołysz; Sylwia Grodecka-Gazdecka; Błażej Rubiś
Journal:  Genes (Basel)       Date:  2022-04-21       Impact factor: 4.141

3.  ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel.

Authors:  Tristan M Sissung; Caitlin E Baum; John Deeken; Douglas K Price; Jeanny Aragon-Ching; Seth M Steinberg; William Dahut; Alex Sparreboom; William D Figg
Journal:  Clin Cancer Res       Date:  2008-07-15       Impact factor: 12.531

4.  Carboplatin/taxane-induced gastrointestinal toxicity: a pharmacogenomics study on the SCOTROC1 trial.

Authors:  Y J He; S J Winham; J M Hoskins; S Glass; J Paul; R Brown; A Motsinger-Reif; H L McLeod
Journal:  Pharmacogenomics J       Date:  2015-07-21       Impact factor: 3.550

5.  Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer.

Authors:  C K Lee; H Gurney; C Brown; R Sorio; N Donadello; G Tulunay; W Meier; M Bacon; J Maenpaa; E Petru; N Reed; V Gebski; E Pujade-Lauraine; S Lord; R J Simes; M Friedlander
Journal:  Br J Cancer       Date:  2011-07-12       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.